Background/Aims: Changes in estradiol that inhibits bone resorption were
INTRODUCTION
Several reports have appeared since bone metabolic disorders after gastric surgery were first reported by Sarasin[1, 3, 6, 7, 9, 11, 13, 14, 16, 17, 18, 19] . The causes given for bone metabolic disorders after gastric cancer surgery included defective absorption of calcium and vitamin D because of gastrectomy [6, 7] and reduced food consumption [14] . However, doubts remain weather the body should initiate a defensive reaction to the progression of bone disorder caused by such metabolic changes or not. Therefore, we investigated changes in estradiol that suppresses bone resorption by inhibition of osteoclasts [4, 5, 12] .
MATERIALS and METHODS
Women who might show effects of menstruation were excluded because estradiol was examined. The subjects were 17 men with a mean age of 60.4 ± 12.3 years (age range: 35 to 80 years) who had undergone gastrectomy for gastric cancer and were followed as outpatients without recurrence. The patient characteristics were as follows. The duration after surgery until bone assessment was a mean of 3.5 ± 3.8 years (0.2 to 13.8 years). The period was less than 2 years in 9 patients (57.7 ± 13.4 years of age) and 2 years or longer in 8 patients (63.5 ± 11.0 years of age). The surgical procedure was total gastrectomy with Roux-Y reconstruction in 4 patients, Billroth-I reconstruction in 9 patients and Billroth-II reconstruction in 4 patients ( Table 1) .
Informed consent was obtained from all patients beforehand for participation in bone tests and blood sampling. Estradiol was measured by the electrochemiluminescent immunoassay (ECLIA) (normal range: 13-42 pg/mL).
Microdensitometry (MD) was applied for assessment of bone disorder.
Radiographs were simultaneously taken of the second metacarpal bone and an aluminum step wedge, and the images were analyzed by computer for evaluation of six microdensitometric parameters. Then the severity of bone disorder was expressed in terms of the scores for each of the 6 parameters, and the total score was used for overall evaluation of bone disorder (normal, initial, Grade I, II, III).
The results obtained by this method are reported to show a good correlation with the results of the vertebral evaluation method developed in the Jikei University School of Medicine. Bone disorder of Grade I or worse is considered to require treatment [8] .
Statistical analysis was conducted using Student's t-test with P < 0.05 taken as significant.
RESULTS

1) Bone atrophy
Bone disorder requiring treatment was observed in 6 out of the 17 patients (35.3%). Bone atrophy was evaluated as normal in 10 patients (58.8%), initial stage in 1 patient (5.9%), Grade I in 3 (17.6%) and Grade III in 3 patients (17.6%).
2) Estradiol and bone disorder
Estradiol showed higher than normal values in 10 patients (58.8%). When bone disorder was investigated by dividing the patients in a high estradiol group and a normal estradiol group, bone disorder in the high estradiol group was Grade III in 2 patients, grade I in 3 patients and normal in 5 patients. In the normal group, bone disorder was Grade III in 1 patient, initial stage in 1 patient and normal in 5 patients. The percentage of patients with Grade I or higher bone disorder requiring treatment was 5 out of 10 patients (50%) in the high estradiol group and 1 out of 7 patients (14.3%) in the normal group. The incidence of bone disorder was higher in the high estradiol group, but the difference was not significant (Table 2 ).
In patients with Grade I or Grade III bone disorder requiring treatment and patients with initial stage or normal bone disorder not requiring treatment, the blood levels of estradiol were 58.2 pg/mL and 44.3 pg/mL respectively. The value in patients requiring treatment was higher but the difference was not significant (P = 0.119) (Fig. 1) .
In this study, a multivariate analysis was not performed because significant differences were not observed for any factors.
DISCUSSION
Various sequelae following gastric cancer surgery including the dumping syndrome have been reported. Recently reports on bone metabolic changes and a higher risk for bone fractures in patients after gastric cancer surgery have appeared[3, 9, 13, 19] . We reported reduced food consumption [14] as a cause of bone disorder after gastric cancer surgery and the usefulness of vitamin D preparations in the treatment of bone disorder [15] . Doubts remain however because the body should initiate some kind of reaction to the prevent progression of bone disorder after gastric cancer surgery. Therefore, we investigated changes in estradiol that inhibits bone resorption to determine if an in vivo response to resist bone disorder occurs.
Estradiol is known to suppress the activity of osteoclasts by inhibition of IL-6 and to prevent osteoporosis by direct action on osteoblasts [5] . It has also been reported that estradiol inhibits bone metabolic turnover [4] . In women, a sharp reduction in bone mass is found around the time of menopause, which causes osteoporosis. Animal studies in male aromatase knockout mice have revealed reduced bone mass, which was normalized by estrogen replacement [10] .
Reduced bone mass has also been reported several times in men with an aromatase gene mutation, suggesting the importance of estrogen in bone metabolism in men [2, 12] .
In the present study, only men were used as subjects to avoid the effect of menopause. Increases of estradiol above the normal range were found in about 60% of the male patients. This was a very interesting change considered to be a feedback reaction to inhibit bone loss or inhibition of the bone metabolic turnover rate.
CONCLUSIONS
Although it was not statistically significant, the elevation of estradiol observed in patients with progressive bone disorder suggested that in vivo inhibition of enhanced bone metabolism occurs after gastric cancer surgery. Fig. 1 Bone disorder and blood levels of estradiol Blood levels of estradiol were 44.3 ± 14.7 pg/mL in the group not requiring treatment of bone disorder (normal, initial stage) (n = 11) and 58.2 ± 19.8 pg/mL in the group requiring treatment (Grade I, II or III) (n = 6). The values were higher in the group requiring treatment but the difference was not significant (p=0.119). 
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